NCT00727311View on ClinicalTrials.gov

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

2,302

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hepatitis C, ChronicHepatitis C
Interventions
BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031) injector

PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling

DRUG

Rebetol (ribavirin; SCH 18908)

Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00727311 - Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) | Biotech Hunter | Biotech Hunter